What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Post-myocardial infarction associated depression (n=15719). Intervention: Antidepressants (SSRIs, TCAs, mirtazapine) vs. Conventional treatment excluding antidepressants. Primary outcome: Depression severity after long-term follow-up (SMD -1.023, 95% CI -1.671– -0.375).

April 23, 2025Open Access

Efficacy and safety of antidepressant in post-myocardial infarction associated depression: a meta-analysis and systematic review

Q: What does this research mean for the field?

Antidepressant treatment effectively reduces depressive symptoms and the risk of myocardial infarction recurrence in patients with post-MI depression, without increasing adverse cardiac events or all-cause mortality. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

HWHongquan WanCenter for Biologics Evaluation and Research LHLi HeGuizhou Normal University SLShuxin LuanJilin University

Resultado clave

Antidepressant treatment significantly reduced depression scores (SMD -1.023) and the risk of myocardial infarction recurrence (HR 0.787) without increasing adverse cardiac events or all-cause mortality.

Diseño del estudio

Tipo

Meta-Analysis (n=15,719)

PICO estructurado

Do antidepressants improve depression scores and reduce adverse cardiac events in patients with post-myocardial infarction depression?

Población

Patients with post-myocardial infarction (MI)-associated depression (pooled from 12 studies)

Intervención

Antidepressants as a class

Comparador

Control group

Resultado

Depression scores after long-term follow-uppatient reported

Antidepressants effectively improve depressive symptoms and may reduce the risk of MI recurrence in patients with post-MI depression without increasing adverse cardiac events.

Resultado numérico

Estimación del efecto: SMD -1.023 (95% CI -1.671– -0.375)

Limitaciones

21 articles were excluded due to lack of access to full-text publications, which could introduce selection bias
Insufficient data on the specific types and dosages of antidepressants used, preventing subgroup analyses
Only SSRIs and mirtazapine were included, limiting the generalizability of the findings
Reliance on standardized mean differences (SMD) to combine depression scores may exaggerate effect sizes
Did not assess treatment acceptability or adherence beyond the adverse event profiles
Potential short-term effects of acute depressive episodes were not explored

Resumen

OBJECTIVE: This study aimed to summarize the available data and assess whether antidepressants are effective and well-tolerated in the treatment of post-myocardial infarction (MI)-associated depression. MATERIALS AND METHODS: A comprehensive search of public databases (PubMed, Embase, Web of Science, Ovid, EBSCO, and the Cochrane Library) was conducted for publications on interventions for post-MI depression before October 2024. Keywords included post-myocardial infarction depression, antidepressants, myocardial infarction, and depression. Pooled data were analyzed using Stata software. RESULTS: A total of twelve studies were included. At baseline, no significant difference was observed in depression severity between the antidepressant treatment and control groups (pooled SMD = -0.022, 95% CI: -0.087-0.044). Antidepressant treatment significantly reduced depression scores after long-term follow-up (pooled SMD = -1.023, 95% CI: -1.671- -0.375). The incidence of adverse cardiac events was not significantly higher in the treatment group compared to the control group (pooled HR = 0.893, 95% CI: 0.793-1.005). Antidepressants did not increase the risk of all-cause mortality (pooled HR = 0.957, 95% CI: 0.699-1.311), and there was no significant difference in the risk of rehospitalization for heart disease (pooled HR = 1.070, 95% CI: 0.820-1.398). Antidepressant treatment was associated with a reduced risk of MI recurrence (pooled HR = 0.787, 95% CI: 0.693-0.894) and revascularization procedures (pooled HR = 0.858, 95% CI: 0.755-0.975). Moderate-certainty evidence (GRADE assessment) supports antidepressant efficacy in improving depressive symptoms, while low-certainty evidence suggests potential cardiac risk reduction. CONCLUSION: This meta-analysis demonstrates that antidepressants are effective and well-tolerated in the treatment of post-MI depression. Antidepressants can improve depressive symptoms without adversely affecting long-term prognosis. The clinical application of these findings should consider the moderate certainty for symptom improvement and low certainty for MI recurrence benefits.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo